Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meglumine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 10/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MTTP | P55157 | 3/20 | 0.34 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.33 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239482 | 0.88 | SERPINE1 (0.47) | SERPINE1GGPS1CYP1A2VKORC1LTB4R2 | |
| SCHEMBL1854363 | 0.79 | GGPS1 (0.38) | SERPINE1GGPS1VKORC1LTB4R2 | |
| SCHEMBL1852378 | 0.79 | ALOX5 (0.42) | GGPS1CYP1A2MTTPVKORC1 | |
| SCHEMBL4313217 | 0.75 | MTTP (0.38) | GGPS1CYP1A2MTTPVKORC1 | |
| SCHEMBL1854365 | 0.73 | ALOX5 (0.37) | GGPS1CYP1A2MTTP | |
| Meglumine SCHEMBL6421775 | 0.73 | FFAR1 (0.39) | SERPINE1 | |
| SCHEMBL4313213 | 0.71 | ALOX5 (0.38) | GGPS1CYP1A2TSHRMTTPGPR52 | |
| SCHEMBL6789536 | 0.70 | ALOX5 (0.38) | GGPS1CYP1A2MTTPVKORC1 | |
| SCHEMBL1853055 | 0.69 | MME (0.40) | GGPS1MTTPVKORC1 | |
| SCHEMBL4324770 | 0.69 | ALOX5 (0.46) | GGPS1CYP1A2MTTPVKORC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | SERPINE1 3132/4885GGPS1 515/4885CYP1A2 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.